Evidence map›Paper›PMID 21198669›Full record

ReviewImmunological reviews2011

Immunology of gut mucosal vaccines.

Marcela F Pasetti, Jakub K Simon, Marcelo B Sztein, Myron M Levine

Registry-linked trialAbstract readReview
In one paragraph

Review in Immunological reviews, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05475379 (A Randomized Control, Double Blinded, Non-inferiority Trial to Evaluate the Immunogenicity and Safety of Typhoid Vi Conjugate Vaccine 'Typhocon' in Bangladeshi Healthy Population), which is not on this map. Cited by 112 papers.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05475379 phase1 / phase2completednot on this mapstarted 2022, after this paper: background citation

A Randomized Control, Double Blinded, Non-inferiority Trial to Evaluate the Immunogenicity and Safety of Typhoid Vi Conjugate Vaccine 'Typhocon' in Bangladeshi Healthy Population

TypeinterventionalSponsorInternational Centre for Diarrhoeal Disease Research, BangladeshRan2022 to 2023Enrolled630ConditionsTyphoidArmsTyphoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT)
3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 241 citations in OpenAlex.

  1. Trial
  2. A phase I trial of WRSS1, aHuman vaccines & immunotherapeutics · 2019
    Trial
  3. Trial
  4. A double-blind randomized controlled study to evaluate the efficacy of low-dose oral interferon-alpha in preventing hepatitis C relapse.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2014
    Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Supramolecular Peptide Self-Assemblies Facilitate Oral Immunization.ACS biomaterials science & engineering · 2024
    Article
  14. Recent development of oral vaccines (Review).Experimental and therapeutic medicine · 2024
    Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. The Bacterial Spore as a Mucosal Vaccine Delivery System.International journal of molecular sciences · 2023
    Review

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Marcela F PasettiCenter for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore St., Room 480, Baltimore, MD 21201, USA. mpasetti@medicine.umaryland.edu
Jakub K Simon
Marcelo B Sztein
Myron M Levine
University of Maryland, Baltimore · US

Funding

Vaccine strategy for broad spectrum protection agains non-typhoidal salmonellU54AI057168 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI WHITE, JUDITH M. · 2003 to 2013
$91.5M
Wild-type S. typhi Infection in Humans: Integrated Immunoprotective MechanismsU19AI082655 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI FASANO, ALESSIO · 2009 to 2018
$27.8M
IMMUNE MECHANISMS OF PROTECTION IN S TYPHI VACCINESR01AI036525 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Marcelo B. Sztein · 1994 to 2026
$12.2M
RECOMBINANT &LIVE ORAL SALMONELLA TYPHI HYBRID VACCINESR01AI029471 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI LEVINE, MYRON MAX · 1990 to 2008
$3.7M
A. L. lactis-based vaccine for children with broad spectrum for enteric pathogensR01AI089519 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PASETTI, MARCELA F, PICKING, WENDY L. · 2010 to 2014
$3.2M
Immune Responses to Biodefense Vaccines Early in LifeR01AI065760 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PASETTI, MARCELA F · 2006 to 2010
$1.8M
Immunological Correlates of Protection in ShigellosisK23AI065759 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI SIMON, JAKUB K · 2005 to 2009
$809k
RECOMBINANT &LIVE ORAL SALMONELLA TYPHI HYBRID VACCINESR21AI029471 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI LEVINE, MYRON MAX · 1997 to 1997
–
NIAID NIH HHS K23 AI065759NIAID NIH HHS K23AI065759NIAID NIH HHS R01 AI029471NIAID NIH HHS R01 AI036525NIAID NIH HHS R01 AI065760NIAID NIH HHS R01 AI065760-01NIAID NIH HHS R01 AI089519NIAID NIH HHS R21 AI029471NIAID NIH HHS U19 AI082655NIAID NIH HHS U54 AI057168NIAID NIH HHS U54 AI57168
6 · The paper itself

Abstract

Understanding the mechanisms underlying the induction of immunity in the gastrointestinal mucosa following oral immunization and the cross-talk between mucosal and systemic immunity should expedite the development of vaccines to diminish the global burden caused by enteric pathogens. Identifying an immunological correlate of protection in the course of field trials of efficacy, animal models (when available), or human challenge studies is also invaluable. In industrialized country populations, live attenuated vaccines (e.g. polio, typhoid, and rotavirus) mimic natural infection and generate robust protective immune responses. In contrast, a major challenge is to understand and overcome the barriers responsible for the diminished immunogenicity and efficacy of the same enteric vaccines in underprivileged populations in developing countries. Success in developing vaccines against some enteric pathogens has heretofore been elusive (e.g. Shigella). Different types of oral vaccines can selectively or inclusively elicit mucosal secretory immunoglobulin A and serum immunoglobulin G antibodies and a variety of cell-mediated immune responses. Areas of research that require acceleration include interaction between the gut innate immune system and the stimulation of adaptive immunity, development of safe yet effective mucosal adjuvants, better understanding of homing to the mucosa of immunologically relevant cells, and elicitation of mucosal immunologic memory. This review dissects the immune responses elicited in humans by enteric vaccines.

Indexed as

Immunity, MucosalAdjuvants, ImmunologicAdministration, OralEnterobacteriaceae InfectionsGastrointestinal TractHumansImmunoglobulin A, SecretoryImmunoglobulin GIntestinal MucosaPoliovirus Vaccine, OralRotavirus VaccinesVaccinesVaccines, AttenuatedAdjuvants, ImmunologicImmunoglobulin A, SecretoryImmunoglobulin GPoliovirus Vaccine, OralRotavirus VaccinesVaccinesVaccines, Attenuated

Identifiers

PMID21198669
PMCPMC3298192
OpenAlexW1901003958

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.